Andrew Solomon is a Neurology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 South Prospect St.
Neurology
Burlington, VT 05403
Telephone
802-847-4589Registry record last updated 20 Jun 2011.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Healthcare KGaAProgram year20256 payments$22,796openpaymentsdata.cms.gov ↗
- EMD Serono, Inc.Program year20256 payments
- Genentech USA, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
40%gamma-Aminobutyric Acid-ergic Agonist26.9%Baclofen100%Part D≥48 patientsCentral alpha-2 Adrenergic Agonist13.2%Tizanidine Hcl100%Part D≥25 patientsNervous system
35.8%Gabapentinoids17.3%Gabapentin100%Part D≥29 patientsPotassium Channel Blocker6.1%Dalfampridine Er100%Part D<11 patients+ 5 more classes in this area
Cancer & immunology
20.8%Other immunostimulants10.5%Glatiramer Acetate35%Glatopa33%Copaxone32%Part D<11 patientsCD20-directed Cytolytic Antibody6.4%Kesimpta Pen100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2022 per NIH RePORTER. The latest:
- Improving Diagnosis of Multiple Sclerosis Through the Integration of Novel Imaging and Laboratory Biomarkers
University of Vermont & St Agric College
FY2022$139,783K02NS109340 - Improving Diagnosis of Multiple Sclerosis Through the Integration of Novel Imaging and Laboratory Biomarkers
University of Vermont & St Agric College
FY2021$192,792K02NS109340 - Improving Diagnosis of Multiple Sclerosis Through the Integration of Novel Imaging and Laboratory Biomarkers
University of Vermont & St Agric College
FY2020$193,783K02NS109340
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”